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The motivation of this study is to demonstrate the practicality of producing slow release and 
fast release products in a single-step hot melt extrusion (HME) process. HPMCAS as the carrier 
material showed good potential in monolithic controlled release formulations for the model 
drug, carbamazepine (CBZ). As binary formulations, CBZ-HPMCAS extrudates showed zero-
order release over 24 hours which was accompanied by the swelling of the extrudates. A range 
of functional excipients was used at low quantities to modulate the release rate. The release 
rates of the HME extrudates could be either accelerated by the incorporations of low quantities 
(5% w/w) of soluble additives or further sustained by adding lipid excipient, Gelucire 50/13. 
Clear phase separations of the soluble additives including crosscarmellose sodium, sodium 
starch glycolate, maltodextrin and lactose in the extrudates led to higher interior porosity and 
quicker erosion in comparison to the binary extrudates. The phase separated Gelucire in the 
extrudates led to the substantial swelling of the extrudates and resulted in further prolonged 
drug release. This study provided clear formulation strategies for modulating the drug release 
rate from controlled release formulation prepared directly by single-step HME. In addition, this 
research work also evaluates for the first time HME extrudates simultaneous swelling and drug 
release using this UV imaging technique. The whole dose cell of this instrumentation is utilised 
to provide insights into the dissolution process of solid dispersions prepared by HME. 
 
Keywords: Controlled release drug delivery, amorphous solid dispersion, hot melt extrusion, 




Hot melt extruded (HME) solid dispersions have been widely used as a formulation strategy to 
improve the dissolution rate of poorly soluble drugs but less commonly reported for producing 
sustained/controlled release formulations [1, 2]. The HME extrudates traditionally have to be 
downstream processed into powder form to allow further tableting or capsules filling. 
Controlled release products can improve patient compliance by reducing the dose frequency 
and therapeutic outcome due to more stable plasma drug concentration in comparison to non-
controlled released products [3]. This study reports the use of the single-step HME process to 
directly manufacture cylindrical shaped monolithic solid dispersion based extrudates as the 
finished product, which can be directly filled in capsules for oral controlled release of drugs. 
Such a shape can also allow easy control of the drug release rate when either diffusion or 
surface erosion are the dominate the release mechanism [4]. Therefore, from a manufacturing 
point of view, HME carries clear advantages as a readily scalable and a single-step method for 
producing amorphous solid dispersion based controlled release products.  
 
In addition to releasing the API in a controlled manner, the challenge of developing monolithic  
controlled release formulations based on amorphous solid dispersions containing poorly 
soluble drug is that the prolonged exposure to the GI fluid could increase the risk of the 
recrystallization of the drug in the dispersion matrices [5]. If the drug is recrystallized instead 
of molecularly dispersed in the polymeric matrix, the release rate is limited by the dissolution 
rate of the crystalline drug particles, but not purely governed by other mechanisms such as 
matrix erosion and diffusion of the drug molecule through the matrix materials. In order to 
minimise the drug recrystallization in a solid dispersion based controlled release matrices, the 
polymer excipient used in the matrices should be able to not only control the release rate of the 
drug, but also prevent the drug crystallisation in the matrix during the course of dissolution. In 
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this study, the polymer, HPMCAS, which has crystallisation inhibition properties, was used to 
form the matrix of the extrudates [6-8]. HPMCAS is a one of a group of widely used 
pharmaceutical enteric polymers, which can be used in the formulation development of 
controlled release formulations targeting the intestines. HPMCAS can be obtained with a 
predetermined ratio of hydrophilic succinate groups and hydrophobic groups such as the acetyl 
and methoxy substituents [9]. The succinate moiety ionisation at high pH results in an increased 
solubility and dissolution rate compared to the un-ionised state at low pH. Furthermore, the 
hydrophobic groups of HPMCAS play an important role in supressing the amorphous drug 
mobility in a HPMCAS based solid dispersion of and inhibiting the drug recrystallisation due 
to the hydrophobic interaction between drug and HPMCAS [10, 11]. With such intrinsic 
properties, it is reasonable to predict that if HPMCAS was used to form the HME monolithic 
solid dispersions, it should be able to hold its structural integrity during drug dissolution and 
inhibiting the crystallisation of amorphous poorly soluble drugs, both in solid dispersions and 
in solutions [12-15]. From the processing prospective, HPMCAS–LF, the low-fine grade of 
HPMCAS, has been reported to be the most stable grade for HME with the lowest level of free 
acid released during HME even at high HME temperature and speed [16].  Therefore, LF grade 
was used in this study.  
 
Carbamazepine (CBZ) was selected as the model drug. It is a well-documented, poorly water-
soluble drug. used as an anticonvulsant and specific analgesic for trigeminal neuralgia in the 
treatment of epilepsy and neuropathic pain, [17, 18]. Clinically, controlled release CBZ 
products (Tegretol® prolonged release and Carbagen® SR) have demonstrated fewer side 
effects than immediate release CBZ products [19, 20]. However, they are manufactured by 
multi-step tabletting process. The motivation of this study is to demonstrate the practicality of 
producing slow release and fast release products in a single-step process. To modulate the CBZ 
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release rate of HPMCAS based extrudates, disintegrants, pore formers and lipid excipients 
were added to the HME extrudates. These were crosscarmellose sodium, Na starch glycolate, 
crosspovidone, maltodextrin, α-lactose monohydrate and Gelucire 50/13 The intention of using 
disintegrants and pore-formers in the extrudates was to increase the drug release rate by 
speeding up the water penetration and disintegration of the HPMCAS matrices; whereas adding 
the swellable lipid excipient, Gelucire 50/13, was intended to slow down the release rate by 
increasing the swelling and reducing the breakdown of the HPMCAS matrices. In order to 
attempt to visualise the swelling and erosion process in real time, this work also evaluates for 
the first time the feasibility of using a UV imaging technique that is primarily used in the 
determination of intrinsic dissolution rates (IDR) [21-27]. 
 
2. Materials and methods 
2.1 Materials 
Carbamazepine (CBZ) was purchased from (Molecula, UK). Hydroxypropyl Methylcellulose 
Acetate Succinate (HPMCAS-LF) with the substituent ratios of –CH3, -CH2CH(CH3)OH, -
COCH3, and –COCH2CH2COOH being 1.87, 0.25, 0.48, and 0.37 average number/glucose ring 
unit was kindly donated by Shin-Etsu Chemical Co. Ltd. (Tokyo, Japan). Gelucire 50/13, 
crosscarmellose sodium (Can) and sodium starch glycolate (NaSG) were kindly donated by 
Gattefosse (Saint-Priest, France), IMCD UK Ltd (Sutton, UK) and Roquette (Lestrem, France), 
respectively. Crosspovidone (Polyplasdone-XL) (CP) was kindly donated by Ashland 
(Limavady, UK), maltodextrin (MD) and α-lactose monohydrate were purchased from (Sigma 
Aldrich, UK).  
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2.2 Preparation of hot-melt extruded (HME) filaments 
HME filaments were prepared using a co-rotating twin screw Haake Minilab extruder (Thermo 
Fisher, Karlsruhe, Germany) with a 2 mm orifice die. The materials were weighed (10 g) and 
pre-mixed via mortar and pestle for 5 minutes. For each experiment, 7 g of the mixture was fed 
manually into extruder. All the formulations were extruded at 150°C for CBZ-loaded (20% 
w/w loading) formulations, 100 rpm screw speed and the retention time was 5 minutes. During 
the flushing (the exiting period of the filament from the die) period, the screw speed was 
decreased to 30 rpm. It is worth noting that the extrusion temperature used is above the reported 
dehydration temperature of lactose monohydrate [28]. The melted strands were guided onto a 
conveyer belt using a circular die of 1.75 mm diameter and collected continuously. CBZ 
containing extrudates were further used to investigate the effects of additives on the dissolution 
behaviour of the formulations. The HME formulations containing CBZ are summarised in 
Table 1. In all formulations the weight of CBZ was kept constant at 20% of the total weight. 
Excipients were added at the rate of 5% of the total weight of the formulation and Gelucire was 
added at the rate of 15% of the total weight of the formulation. 
 
2.3 Attenuated total reflection-Fourier transform Infrared (ATR-FTIR) Spectroscopy 
The IR spectra of the raw materials, physical mixture and extrudates were collected using an 
FTIR spectrometer (Vertex 70 model from Bruker Optics Limited, United Kingdom) connected 
with single-reflection diamond ATR accessory (MIRacl™, Pike Technologies, United States). 
Thirty-two scans were acquired for each sample with a resolution of 2 cm−1 scanning from 600-
4000 cm-1. All the measurements were carried out on three separate extrudates and analysed 
via Opus software. 
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2.4 Powder X-ray diffraction (PXRD) 
A Thermo ARL Xtra X-ray diffractometer (Thermo Scientific, Switzerland) with a Cu Kα1 X-
ray Tube was used for to study the physical form of raw materials, physical mixture and 
extrudates in the different formulations and the possible changes in the nature of the 
components due to processing. The voltage and current of the X-beam used were 45 kV and 
40 mA respectively. The angular scanning range was from 5 to 60° with a (2θ) scan type, a 
step size of 0.01° and the scan rate was 4 s/step. 
 
2.5 Differential scanning calorimetry (DSC) 
The DSC experiments were carried out to analyse the raw materials and HME extrudates using 
Q-20 (TA Instrument, Newcastle, USA) at a heating rate of 10 °C/min from 25 to 210 °C. A 
nitrogen purge at a flow rate of 50 ml/min was used and sample weights were in range of 2-3 
mg. TA standard crimped pans and lids were used for all measurements as well as universal 
analysis software for analysing the obtained results.  
 
2.6 UV and visible imaging of HME extrudates 
The surface imaging instrument (SDI2) is a UV dissolution imaging technique. In this study, it 
was used in the simultaneous determination of the swelling and drug release from a select few 
of the HME extrudates (placebo extrudate, H, HG, H-NaSG and HG-NaSG). These selected 
HME extrudates allowed the investigation of the effect of Gelucire on the HPMCAS as well as 
the NaSG effects on the produced extrudates. A schematic of the drug release measurements is 
depicted in Fig. 1a. Fig. 1b also displays how the dosage form is placed inside the whole dose 
cell, the direction of media flow and the measurement zone adapted for swelling evaluation. 
Each extrudate (placebo extrudate, H, HG, H-NaSG or HG-NaSG) was mounted using a 
custom designed stainless steel wire holder featuring two loops to secure the extrudate in place 
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(Fig. 1c). To perform each test the whole dosage cell with glass beads loaded (to help reduce 
turbulence) was inserted and connected to the fluid lines. To determine the swelling effects on 
the extrudates (placebo extrudate, H and HG), a 2 h flow-through assessment was conducted 
to determine the characteristic behaviour of each extrudate. Each experiment was conducted 
using both pH 1.2 and pH 6.8 at 37 °C using a flow rate of 8.2 mL/min. A 520 nm wavelength 
was selected for swelling measurements.  Swelling is referred to as “growth” in the Figures. 
These measurements were taken using the data analysis software supplied with the SDI2 
system and processed using Microsoft Excel™. 
 
The first use of a dual closed loop assessment of drug loaded HME extrudate (H, HG, H-NaSG 
and HG-NaSG) was explored and implemented (Fig. 2). Two beakers containing 900 mL of 
each medium (pH 1.2 and pH 6.8) were placed on stirrer plates and allowed to warm to 37 °C 
before use. To form the first loop, the primary fluid line was connected to the pH 1.2 beaker 
along with the ‘open loop’ waste fluid line. To form the secondary closed loop, the secondary 
fluid line was connected to the pH 6.8 beaker along with the ‘closed loop’ waste fluid line. As 
the SDI2 has the ability to transfuse between different media in situ the software was set to 
clear 70 mL of media during change over to ensure that the pH 1.2 did not contaminate the pH 
6.8 media. Each closed loop experiment was conducted for 6 h (2 h in pH 1.2 before 4 h in pH 
6.8 media). Each experiment was conducted at 37 °C at a flow rate of 4.2 mL/min. A 280 nm 
(for CBZ release from the HME extrudate) and a 520 nm (for the HME extrudate swelling 
(growth) measurements) LED were selected as the light sources. Drug release and growth 
measurements were collected using the supplied data analysis software and processed using 
Microsoft Excel™. Normalisation of growth measurements was achieved by subtracting the 
size of the extrudate at the start of the experiment from the subsequent growth data points 
(Equation 1, where t0 is initial time point and x is the subsequent time point). 
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𝐸𝑥𝑡𝑟𝑢𝑑𝑎𝑡𝑒 𝑔𝑟𝑜𝑤𝑡ℎ 𝑐ℎ𝑎𝑛𝑔𝑒 (%) = (
𝐺𝑟𝑜𝑤𝑡ℎ 𝑜𝑓 𝑒𝑥𝑡𝑟𝑢𝑑𝑎𝑡𝑒 𝑎𝑡 𝑡𝑥−𝑂𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑒𝑥𝑡𝑟𝑢𝑑𝑎𝑡𝑒 𝑤𝑖𝑑𝑡ℎ
𝑂𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑒𝑥𝑡𝑟𝑢𝑑𝑎𝑡𝑒 𝑤𝑖𝑑𝑡ℎ
) 𝑥 100          Eq. 1 
 
2.7 In vitro drug release studies 
All in vitro drug release experiments were performed using the British Pharmacopeial (BP) 
rotating basket method (Copley CIS 8000, Copley Scientific) under sink condition for 24 hours. 
A 100 rpm paddle rotation speed and 900 mL of either HCl dissolution medium (pH 1.2) or pH 
6.8 PBS were used for each test. The temperature of the vessel was controlled at 37 ± 0.5 °C. 
All dissolution tests were performed as 2-stage experiments to mimic the physiological process 
of gastric emptying and the transport of gastric content into the intestinal environment. 
Therefore after 2 hours of dissolution being performed in pH 1.2 HCl, the extrudates were 
removed and the dissolution media was changed to pH 6.8 PBS for the following 22 hours. 
Strands of extrudate containing the equivalent of 10 mg of CBZ were used in 900 ml medium 
to ensure the satisfaction of the sink conditions. 3 ml of the media from each vessel were filtered 
through 0.45 μm filters (Minisart Sartorius, Goettingen, Germany) and sampled at 
predetermined time intervals (0.5, 1, 2, 4, 6, 8, 12 and 24 hours) for the swellable strands and 
(0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6 and 6.5 hours) for the rapidly erodible strands to determine 
the release mechanisms. The amount of CBZ in each sample was measured by an UV 
spectrometer (PerkinElmer Lamda XLS, USA) at 285 nm. All measurements were performed 
in triplicate. 
 
3. Results and discussions 
3.1 Characterisation of binary CBZ-HPMCAS extrudates 
The DSC results of the main components of the extrudates indicate the Tg of the amorphous 
CBZ and HPMCAS at 48.54 ± 1.3 and 123.8 ± 0.2 ºC, respectively (Fig. 3a).  After HME, 
CBZ at 20% drug loading formed clear extrudates with HPMCAS. The DSC result of the drug-
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loaded extrudates displays a single Tg at 77.5 ± 1.5 ºC, confirming the formation of a molecular 
dispersion (Fig. 4a). The fully amorphous nature of the binary extrudates was further confirmed 
by the full halo pattern of the PXRD results. (Fig. 4b). The experimental Tg is higher than the 
Gordon-Taylor equation predicted Tg (69.7 ºC) [29, 30]. Such positive deviation has been 
attributed to the strong specific intermolecular interactions in the literature including hydrogen 
bonding, electron donor-acceptor complexes and ionic interactions [31]. ATR-FTIR confirmed 
the amorphous state of the binary matrix and consistency with a molecularly dispersed system 
but not showing strong signs of hydrogen bonding interactions. Therefore, any intermolecular 
interaction between HPMCAS and CBZ could be dominated by van der Waals interactions 
which are consistent with the hydrophobic interactions proposed by Ueda et al. [14, 15]. 
 
As seen in Fig. 5a, the HPMCAS-CBZ binary extrudates examined by the rotating basket 
method show limited release in the first hours at pH 1.2 media and a continuous zero order 
drug release within the 24 hours in pH 6.8. The fitting of the release data to the zero order 
kinetics can be found in Supplementary Material Table S1. Such sustained release can be 
explained by the over 281% swelling in weight and volume of the binary CBZ-HPMCAS 
extrudates (Table S2) after 12 hours in pH 6.8. This is in clear contrast to the HPMCAS placebo 
extrudates which only showed approximately 30% and 101% increases in weight and in 
volume, respectively, after 12 hours in pH 6.8 (Supplementary Material Fig. S1). A clear 
swelling layer of the CBZ-HPMCAS extrudates can be seen (Fig 5a insert). 
 
Similar swelling behaviour of HPMCAS matrices was reported in the literature [32]. The slow 
erosion/dissolution of the swelled HPMCAS layer was thought to be caused by the drop in the 
local pH due to ionisation of the acid groups on the polymer. This resulted in the pH dropping 
below the threshold necessary for the dissolution of this polymer. [32]. However we would 
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argue that when the succinate groups ionise at pH 6.8, they release hydrogen ions and become 
negatively charged. This should increase electrostatic repulsion which tends to lead to polymer-
polymer repulsion and disentanglement and dissolution. To counter balance this effect, the 
ionisation also can lead to a local increase in ionic strength and therefore an increase in 
shielding of the charges. Therefore the effects generated from the local ionisation of the 
HPMCAS acid groups may not be as large as might be expected on a simple charge model. 
Therefore, whilst an argument about the effect of local pH may not fully explain the slow 
swelling and dissolution of the polymer, the concentration of ions locally due to ionisation may 
reduce charge-charge repulsion and result in a reduction of the rate of swelling and dissolution. 
 
When CBZ is added to the polymer the amount of swelling increases compared to the placebo. 
The most likely cause of this is the increased free volume created by the inclusion of the drug 
enabling polymer disentanglement to occur more easily. Evidence for this is given by the 
decrease in Tg of the mixed system compared to the pure polymer. 
 
3.2 Accelerating the drug release using low quantity additives 
In order to explore the formulation strategies for accelerating the complete drug release from 
the extrudates from 24 hours to 12 hours, a range of additives with 5% (w/w) loading were 
blended in the formulation during HME. These additives are traditionally used as either 
disintegrants (CNa, NaSG, and CP) or diluent/pore formers (MD and LM) in oral dosage forms. 
It was hypothesised that the addition of these excipients could speed up the physical 
disintegration process of the extrudates, subsequently the drug release rate.   
 
Single Tgs were detected for all ternary extrudates indicating the fully amorphous nature of the 
drug and polymer in the extrudates (Fig. 6a and b) which is further confirmed by the PXRD 
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(Fig. 7a). The phase separation of the additives were not detected by the DSC, but suggested 
by the SEM (Fig.8) The ATR-FTIR data shown in Fig. 7c show no significant changes of CBZ 
peaks in comparison to the HPMCAS-CBZ binary extrudates indicating that the addition of the 
additives had no effect on the intermolecular interactions between CBZ and HPMCAS. The 
DSC results indicate slight shifts in Tg to lower temperatures in comparison to the binary 
HPMCAS-CBZ extrudates. This may be ascribed to the increased the relative ratio of CBZ to 
HPMCAS (20:75 w/w) in the ternary formulation than the binary system (20:80 w/w). From 
the SEM images shown in Fig. 8, it can be confirmed that except H-CP, all other additives are 
phase separated from the HPMCAS-CBZ dispersion. Significant levels of porosity were 
observed in the cross-section of these ternary extrudates with the exception of H-CP. The 
underpinning mechanisms for the formation of the internal pores is out of the scope of this 
study and will be discussed in a separation study.  
 
In comparison to the binary HPMCAS-CBZ extrudates (zero order release rate K= 
0.068%/min, shown in Supplementary Material Table S1), much faster drug release was 
achieved for all ternary extrudates. The samples H-LM, H-CNa, H-NaSG and H-MD all 
demonstrated first order release kinetics with very similar rate constants (average zero order 
release rate K= 0.395 +/-0.01 %/min, shown in Supplementary Material Table S1) 
approximately 6 times faster than the binary system. H-CP was exceptional in that its release 
profile could not be fitted to a zero order process but could be fitted to a first order process with 
rate constant of 0.004 %/min (Supplementary Materials Table S1). Because of the low number 
of data points this fit may not be unique but it does indicate a process in which the rate depends 
on the amount of drug available for release. Although the rate process of H-CP is different from 
other formulations, the half-life is similar to that for the other ternary systems at about 4 hours. 
With 5% (w/w) addition of CP in the binary system, the change in Tg may be too subtle to be 
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detected by DSC (Fig. 6b). Therefore it is difficult to use DSC to determine whether CP formed 
homogeneous molecular dispersion with HPMCAS and the drug. However it is clear in the 
SEM images (Fig. 8) that at least there is no micron scale phase separation in the H-CP 
extrudates. This continuous morphology of H-CP (in contrast to the highly porous interior of 
other formulations) may contribute to the difference in rate process. A homogeneously 
distributed soluble additive such as CP will enhance water absorption into the matrix and in 
dissolving will uniformly erode the matrix. However if the material is not homogeneously 
distributed its swelling or dissolution will fracture the matrix or create pores filled with water.      
 
H-LM showed fastest release rate among all ternary extrudates. This could be caused by the 
local dissolution of the lactose particles which create high sugar solution in the pockets (which 
were previously occupied by lactose particles). This localised high sugar solution would 
generate high osmotic pressure which would tend to result in the faster ingress of water and 
consequent swelling of the lactose solution filled pockets thus contributing to the faster drug 
release from H-LM extrudates.  
 
The results from the rotating basket method are confirmed by the UV imaging results. Using 
H-NaSG as an example, Fig. 9 depicts the UV images obtained from the SDI2 instrumentation 
in both the UV and visible wavelength. The UV images in the UV region show no significant 
CBZ release in the pH 1.2 media for the binary extrudates. As seen in Fig. 9, there is an increase 
in the CBZ release in the pH 1.2 media with the addition of NaSG to the extrudates. This agrees 
well with the approximately 5% release observed in the conventional dissolution test for H-
NaSG within 1 hour of dissolution in pH 1.2 (Fig. 5a). The red dashed lines in Fig. 9 after the 
2 h images are where the media change to pH 6.8 occurs. A change in the pH shows significant 
amounts of drug being released as a result of this pH shift. The results correlate well with Fig. 
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5a where the incorporation of the NaSG brought about significant increases in the CBZ release 
in pH 6.8.  
 
Little erosion was observed in the binary extrudate of HPMCAS-CBZ in both media. Fig. 10a 
showed there was hardly any swelling to occur for the binary extrudate in pH 1.2. The 
introduction of the pH 6.8 brought about the swelling of the filament (Fig. 10a). This was also 
evident in Fig. 10b which is a zoomed in image of the self-same extrudate in pH 6.8 (after 60 
min in the pH 6.8 media). This showed an increase in swelling to occur to due to the media 
ingress into the extrudate and it was also possible to visualise the gel layer. The incorporation 
of NaSG into the formulation brought about changes in the swelling at pH 1.2 when compared 
with the binary filament (Fig. 10a). This may be attributed to the porosity of the H-NaSG which 
encourage rapid water uptake into the extrudates. The extrudate continued to swell to a greater 
extent in pH 6.8 till after ~180 min when extrudate degradation can be observed. This continues 
to occur as can be visualised from Fig. 10c (zoomed in image after 180 min in pH 6.8 showing 
the gradual extrudate degradation). The filament continues to degrade past its normalised size 
(orange circle in Fig. 10a). 
 
3.3 Sustaining the drug release using lipid additives  
Gelucire 50/13 is one of the Gelucire group of self-emulsifying excipients often used in oral 
preparations. Gelucire 50/13 has been reported to exhibit significant water uptake and gel 
forming ability. [33] . It has been co-extruded with polymers for forming solid dispersions for 
taste masking and modified release applications [34-36]. It was selected to blend with 
HPMCAS in this study to modify the swelling behaviour of the HPMCAS matrices and allow 
further prolonged release of CBZ. As seen in Fig. 6, with a small amount of Gelucire remains 
phase separated as shown by the small residual melting peak in the DSC. Small amounts of 
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crystalline Gelucire are also evident in the PXRD results shown in Fig. 7b. As with the ternary 
extrudates, the ATR-FTIR spectra of Gelucire-containing extrudates show no shifts of the 
signature IR peaks of amorphous CBZ and HPMCAS indicating that the addition of Gelucire 
had no effect on the state of the drug and the interaction between CBZ and HPMCAS in the 
extrudates and that no specific interaction with Gelucire is evident.   
 
As seen in Fig 5b, with the exception of the HG-LM, all the samples containing Gelucire show 
a much slower release profile than the samples without Gelucire. All release rates are zero 
order, including the CP containing sample which showed a first order rate process in the H-CP 
sample (Supplementary Materials Table S1). HG without any other additives exhibited slowest 
drug release rate (K=0.038 %/min, T50 =21 hours). This is about half the rate seen in sample 
H. H-CAN, H-Na SG and H-MD and HG-CP had rate constants ranging from 0.052 to 0.066 
%/min which are 6 to 7 times slower than the samples without Gelucire.  
 
HG-LM was exceptional in that its rate was very similar to that of the corresponding sample 
without Gelucire indicating that for this excipient the nature of the excipient itself determined 
the rates of release.  Whereas for the remainder the presence of Gelucire was the determinant 
of the release rate. With the exception of the HG-LM sample, the volumes increased in linear 
fashion but the weight, although increasing, tended to level off at longer times indicating that 
some erosion may be taking place. 
 
The slow hydration of the placebo is consistent with the results seen for the samples without 
Gelucire and is likely to be due to the same action of CBZ in increasing the free volume of 
HPMCAS thus enabling easier disentanglement. 
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In contrast to the ternary extrudates without Gelucire, which dissolved through surface erosion, 
the Gelucire-containing extrudates (except HG-LM) all show similar rates of the continuous 
swelling. These were up to 450-650% by 24 hours, implying that the addition of the low 
quantity additives had a minimal effect on the matrices. The SEM images shown in Fig. 8 
reveal the much less porosity at the surfaces of the Gelucire containing extrudates in 
comparison to the Gelucire-free extrudates.  
 
HG-NaSG was used as an example to further study the impact of Gelucire 50/13 on the drug 
release behaviour. The UV (280 nm LED) and visible (520 nm LED) were used to 
simultaneously measure the CBZ release and swelling from the binary extrudates formulated 
with Gelucire and NaSG (HG-NaSG). The images in Fig. 9 suggest the incorporation of 
Gelucire further increases CBZ release in the pH 1.2 media in comparison to H-NaSG 
(approximately 7% within 1 hour in pH 1.2). The order for drug release from the extrudates 
therefore in pH 1.2 prior to the pH shift to 6.8 was H < H-NaSG < HG-NaSG. This agrees well 
with the dissolution data for the first 2 hours in pH 1.2 (Fig. 5). In terms of the trend of the 
swelling behaviour of the extrudates, the trend is H < HG-NaSG < H-NaSG. The addition of 
Gelucire increased the swelling of the extrudates in pH 1.2 in comparison to binary extrudates, 
but reduced the swelling when it is compared to H-NaSG (Fig 10a). This agrees well with the 
swelling data of the extrudates tested under conventional rotational basket dissolution 
condition (Supplementary Materials, Table S2 and S3).  
 
The change to pH 6.8 as evidenced in the UV images at 280 nm suggests much faster drug 
release and disintegration of the HG-NaSG extrudates when tested using SDI2 apparatus than 
the results obtained using the conventional dissolution test. It was interesting to note the 
changes to the extrudates in the visible wavelength of 520 nm: clear rapid initial swelling was 
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seen in HG-NaSG up to 2 hours after the pH change to 6.8. After 2 hours in pH 6.8, the rapid 
disintegration of the extrudates into fragments starts to occur. Fig. 10d shows particulates of 
the filaments in the media using the 520 nm LED depicting further degradation of the 
extrudates. This may have contributed to the significantly faster CBZ release observed in the 
SDI2 experiments. It is however important to note that the hydrodynamics of this miniaturised 
flow cell dissolution system (~70 ml volume with constant lamellar flow at 8.2 ml/min) is 
different to that of the standard dissolution system (900 ml with rotational basket) which may 
lead to differences observed with drug release behaviour. As the sample swells the polymer 
chains will disentangle and the mechanical strength of the sample will decrease. If the 
hydrodynamic regime is such that the pressure differences across the sample or the drag forces 
acting on it are sufficient to cause mechanical disruption, then fragmentation and erosion will 
follow. In the flow cell this appears to be the case but not in the rotating basket. In addition, 
the custom-made sample holder may also apply additional mechanical strain to the swelled 
extrudates and contribute to the disintegration of the integrity of the structure. These results 
also highlight the importance of hydrodynamic effects on the in vitro drug release results and 
more in depth investigation is undergoing.  
 
4. Conclusion 
This study proposed the use of HME to directly manufacture controlled release oral 
formulations. HPMCAS-LF showed good potential for being used as the matrix excipient for 
monolithic controlled release formulations. As binary formulations, CBZ-HPMCAS extrudates 
showed zero-order controlled release of CBZ over 24 hours. The intermolecular interactions 
(most likely to be either van der Waals or hydrophobic interactions which were not detected 
by IR) between CBZ and HPMCAS and the microenvironments are responsible for the 
sustained release of CBZ. The release rate of the HME extrudates could be accelerated by the 
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incorporation of low quantities (5% w/w) of additives and sustained further by adding lipid 
excipient, Gelucire 50/13. The highly water-soluble additive, lactose, led to rapid water 
penetration and erosion of the extrudates resulting in a faster drug release rate than the CBZ-
HPMCAS binary extrudates. Clear phase separation of the disintegrants including NaSG, CNa, 
MD and LM in the extrudates led to higher interior porosity and quicker erosion in these 
matrices in comparison to the binary extrudates. The gel-forming ability of Gelucire, which is 
also phase separated in the extrudates, provided the substantial swelling capability of the 
extrudates and further prolongation of the drug release. UV imaging was also able to provide 
direct visualisation and further insights into the simultaneous drug release and swelling/erosion 
phenomena occurring. This study thus provides clear formulation strategies for modulating the 
drug release rate from controlled release formulation prepared directly by HME.  
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H 80 20   
H-CNa 75 20 Crosscarmellose Na/5 - 
H-NaSG 75 20 Na starch glycolate/5 - 
H-CP 75 20 Crosspovidone/5 - 
H-MD 75 20 Maltdextrin/5 - 




HG 60 20 -------- 20 
HG-CNa 60 20 Crosscarmellose Na/5 15 
HG-NaSG 60 20 Na starch glycolate/5 15 
HG-CP 60 20 Crosspovidone/5 15 
HG-MD 60 20 Maltdextrin/5 15 







Figure 1. Set-up of the SDI2 for the assessment of HME filaments for the measurement of 
CBZ release (a), width growth (swelling) (b), custom stainless steel holder to mount HME 







































Figure 2. A schematic representation of the dual closed loop method for the assessment of the 









Figure 4. (a) DSC; (b) PXRD; partial ATR-FTIR data within the wavenumbers of (c) 3600-
2600 cm-1 and (d) 1800-600 cm-1 of the crystalline, amorphous CBZ and extrudates of CBZ-
HPMCAS binary formulation.  
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Figure 5. The 24-hour in vitro drug release of (a) CBZ-HPMCAS-additive ternary extrudates 
and (b) Gelucire-containing extrudates 
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Figure 6. DSC thermograms of the (a) physical mixes and (b) HME extrudates of the CBZ-




Figure 7. PXRD patterns of (a) the CBZ-HPMCAS-additive ternary extrudates and (b) the 
Gelucire-containing extrudates; the partial ATR-FTIR spectra of (c) the CBZ-HPMCAS-
additive ternary extrudates and (d) the Gelucire-containing extrudates 
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Figure 8. SEM images of the comparison of the cross-sections of the CBZ-HPMCAS-
additive ternary extrudates and Gelucire-containing extrudates (freshly prepared by HME). 
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Figure 9. False coloured SDI2 images for the HME extrudates (H, H-NaSG, and HG-NaSG) 
obtained from the SDI2 instrument when the dissolution tests were performed in pH 1.2 for the 
first 2 hours and in pH 6.8 from 2-6 hours. Images depict CBZ release and swelling using UV 
and Vis wavelengths at 280 nm and at 520 nm, respectively.  
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Figure 10. Normalised swelling measurements for the HME extrudates (H, H-NaSG and HG-
NaSG) in (a) pH 1.2 with a pH shift to pH 6.8 obtained from the SDI instrument at 520 nm. 
False-coloured SDI2 swelling images for (b) the H extrudate after 60 min in pH 6.8 showing 
the gel layer due to media ingress; (c) the H-NaSG extrudate after 180 min in pH 6.8 showing 
the degradation as a result of the incorporation of NaSG; (d) the HG-NaSG extrudate after 180 
min in pH 6.8. The disintegrated extrudate particulates can be visualised in the media (as 
highlighted by the red arrows) and may have contributed to the extended release of CBZ seen 
in Figure 5 (b). 
 
 
 
 
